Inhibikase Therapeutics, Inc. (IKT) SEC Filings & Earnings Calls

Cash runway to Phase 3 topline data readout is contingent on full and timely exercise of outstanding warrants, introducing financing risk

“Cash runway to Phase 3 topline data readout (Assuming the full and timely exercise of the outstanding Series A and B Warrants)”

Phase 3 clinical trial risk; IKT-001 is a prodrug of imatinib which had prior safety issues in PAH

“Imatinib is approved for Oncology indications but likely not approved for PAH because of a combination of adverse events and high discontinuation rate” · word for word

Clinical-stage company with no approved products; depends on Phase 3 trial success

“Pre-revenue; net loss $16.4M; cash burn continues”

Dilution risk from ATM and warrant exercises

“25M shares sold to RA Capital; 42.5M pre-funded warrants outstanding”

China supply chain disruption risk

“We currently rely on STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi AppTec Co., Ltd., for the manufacture and supply of drug substance and drug product for our lead product candidate, IKT-001.” · word for word

Clinical trial enrollment and execution risk

“Our Phase 3 clinical study, named IMPROVE-PAH ... is presently enrolling patients with 26 country regulatory approvals and 43 clinical sites activated to date.” · word for word

Financing risk / going concern

“We anticipate that we will need substantial additional funding in connection with our continuing operations.” · word for word

Shareholder dilution from unregistered share issuance

“Item 3.02 filing indicates issuance of unregistered shares”

Still dependent on Phase 3 trial success for approval

“IKT-001 is still in Phase 3; ODD does not guarantee approval”

Dilution from ATM sales

“Sales under at-the-market facility”

Potential future dilution from equity plan shares

“3M additional shares authorized for equity incentives”

Pre-revenue clinical-stage biotech with widening net loss; no approved products; reliance on single lead asset IKT-001.

“Net loss $16.4M vs $13.7M; no revenue; only one pipeline asset in Phase 3.”

No revenue, reliance on future funding

“To date, we have not generated any revenue from the sale of commercial products.” · word for word

Clinical trial execution risk

“We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.” · word for word

Substantial additional funding needed

“We anticipate that we will need substantial additional funding in connection with our continuing operations.” · word for word

Clinical trial execution risk; Phase 3 trial may fail to meet endpoints.

“Phase 3 study with adaptive design; primary endpoints PVR and 6MWD; regulatory approvals pending in multiple countries.”

Cash burn rate increased; net loss widened significantly.

“Net loss $48.3M vs $27.5M; R&D and SG&A expenses rose sharply.”

Capital depletion risk

“If we are unable to successfully raise additional capital on a timely basis or on acceptable terms, our clinical trials and product development could be limited or delayed and our long-term viability may be threatened.” · word for word

Clinical trial failure risk

“Our current and planned clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, or may require additional clinical studies to be undertaken, which would prevent, delay or limit the scope of regulatory approval and commercialization.” · word for word

Single product dependency

“Our business is highly dependent on the success of our initial product candidate, IKT-001, targeting pulmonary arterial hypertension (PAH).” · word for word

FDA regulatory disruption

“Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent thos” · word for word

China manufacturing concentration

“Our current and future product candidates are expected to be manufactured in whole or in part by companies that are located in China.” · word for word

Drug pricing pressure

“Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.” · word for word

Cash burn and no revenue; pre-revenue clinical-stage risk.

“Net loss $35.5M in 9 months; cash $77.3M; no approved products.”